Figures and Tables
From the following article:
PTC124 targets genetic disorders caused by nonsense mutations
Ellen M. Welch, Elisabeth R. Barton, Jin Zhuo, Yuki Tomizawa, Westley J. Friesen, Panayiota Trifillis, Sergey Paushkin, Meenal Patel, Christopher R. Trotta, Seongwoo Hwang, Richard G. Wilde, Gary Karp, James Takasugi, Guangming Chen, Stephen Jones, Hongyu Ren, Young-Choon Moon, Donald Corson, Anthony A. Turpoff, Jeffrey A. Campbell, M. Morgan Conn, Atiyya Khan, Neil G. Almstead, Jean Hedrick, Anna Mollin, Nicole Risher, Marla Weetall, Shirley Yeh, Arthur A. Branstrom, Joseph M. Colacino, John Babiak, William D. Ju, Samit Hirawat, Valerie J. Northcutt, Langdon L. Miller, Phyllis Spatrick, Feng He, Masataka Kawana, Huisheng Feng, Allan Jacobson, Stuart W. Peltz & H. Lee Sweeney
Nature 447, 87-91(3 May 2007)
doi:10.1038/nature05756
Figure 2
Full-length dystrophin is produced in PTC124-treated cultured myotubes.
Full size figure and legend (65K)Figure 3
Rescue of the dystrophic phenotype in muscles of the mdx mouse.
Full size figure and legend (188K)Figure 4
PTC124 activity is selective for readthrough of premature translation termination codons.
Full size figure and legend (156K)



